Disclosed herein are mixed steroidal tetraoxanes having the following structural
formula 1
##STR1##
wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is
H, methyl, ethyl, or isopropyl; R2 is H, methyl, or ethyl; R3 is H, methyl, or
ethyl; R4 is H, methyl, ethyl, tert-butyl, phenyl, p-hydroxyphenyl, p-methoxyphenyl,
or p-nitrophenyl, or
##STR2##
wherein Y is a C1-C4 straight or branched-chain alkoxy,
or
##STR3##
wherein W is N, R5 is hydrogen, methyl, ethyl, n-propyl, isopropyl, or methyl
ethanoate 2-yl, and R6 is hydrogen, methyl, ethyl, or n-propyl, or R5 and R6 are
part of a pyrrolidine or piperidine ring; X is a C1-C4 straight
or branched-chain alkoxy, a primary amino, a N-alkylamino wherein the alkyl is
a straight-chain alkyl groups containing from 1 to 4 carbon atoms, methyl ethanoate-2-yl,
N-phenylamino, p-nitrophenyl, N,N-dimethylamino, N,N-diethylamino, N,N-di(n-propyl)amino,
N-pyrrolidino, or N-piperidino as single compounds, and any mixture of all possible
stereoisomers at C(4). n may be 0, 1, 2, or 3, and methods of making and
using thereof. As disclosed herein, the mixed steroidal tetraoxanes of the present
invention exhibit antimalarial, antibacterial, and antiproliferative activity.
Thus, as disclosed herein, the mixed steroidal tetraoxanes of the present invention
may be used to treat, prevent, or inhibit malaria, bacterial infections, and diseases
and disorders associated with cell proliferation in a subject.
